Polymyxin B hemoperfusion and mortality in abdominal septic shock: Reply

JAMA

Volumn 302, Issue 18, 2009, Pages 1969-1970

  Antonelli, Massimo ^a   Giunta, Francesco ^b   Ronco, Claudio ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERTENSIVE FACTOR; POLYMYXIN B;

GRAM NEGATIVE BACTERIUM; HEMOPERFUSION; HUMAN; LETTER; MEAN ARTERIAL PRESSURE; MORTALITY; PRIORITY JOURNAL; RESUSCITATION; SEPSIS; SEPTIC SHOCK; STATISTICAL ANALYSIS; SURVIVAL TIME;

EID: 70449914904     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1609     Document Type: Letter

References (6)

1. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective- ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338(6):347-354. (Pubitemid 28083906)
2. Napolitano LM, Fabian TC, Kelly KM, et al. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma. 2008;65(2):285-297.
3. Cantaluppi V, Assenzio B, Pasero D, et al. Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med. 2008;34(9):1638-1645.
4. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709.
5. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med. 2005;33(10):2266-2277.
6. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11(2):R47. (Pubitemid 46805281)